These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 9043759)
1. Class I major histocompatibility complex antigens and tumor ploidy in breast and bronchogenic carcinomas. Redondo M; Concha A; Ruiz-Cabello F; Morell M; Esteban F; Talavera P; Garrido F Cancer Detect Prev; 1997; 21(1):22-8. PubMed ID: 9043759 [TBL] [Abstract][Full Text] [Related]
2. Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Redondo M; Concha A; Oldiviela R; Cueto A; Gonzalez A; Garrido F; Ruiz-Cabello F Cancer Res; 1991 Sep; 51(18):4948-54. PubMed ID: 1654207 [TBL] [Abstract][Full Text] [Related]
3. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cordon-Cardo C; Fuks Z; Drobnjak M; Moreno C; Eisenbach L; Feldman M Cancer Res; 1991 Dec; 51(23 Pt 1):6372-80. PubMed ID: 1933900 [TBL] [Abstract][Full Text] [Related]
4. Lack of correlation between codon 12 K-ras mutations and major histocompatibility complex antigens in bronchogenic carcinomas. Redondo M; Rodriguez F; Hortas ML; Concha A; Morell M; Garrido F; Ruiz-Cabello F Cancer Detect Prev; 1997; 21(5):412-7. PubMed ID: 9307844 [TBL] [Abstract][Full Text] [Related]
5. MHC class I antigen expression is inversely related with tumor malignancy and ras oncogene product (p21ras) levels in human breast tumors. Solana R; Romero J; Alonso C; Peña J Invasion Metastasis; 1992; 12(3-4):210-7. PubMed ID: 1294532 [TBL] [Abstract][Full Text] [Related]
6. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Vitale M; Pelusi G; Taroni B; Gobbi G; Micheloni C; Rezzani R; Donato F; Wang X; Ferrone S Clin Cancer Res; 2005 Jan; 11(1):67-72. PubMed ID: 15671529 [TBL] [Abstract][Full Text] [Related]
7. Immune selection in murine tumors. Ph.d thesis. Svane IM; Engel AM APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251 [TBL] [Abstract][Full Text] [Related]
8. HLA-G and its relation to proliferation index in detection and monitoring breast cancer patients. Sayed D; Badr G; Maximous D; Mikhail NN; Abu-Tarboush F; Alhazza IM Tissue Antigens; 2010 Jan; 75(1):40-7. PubMed ID: 20196818 [TBL] [Abstract][Full Text] [Related]
9. HLA class II expression in well differentiated thyroid carcinoma: correlation with clinicopathological features. Knoll MR; Schwab M; Oestreich K; Rumstadt B; Hagmüller E J Exp Clin Cancer Res; 1997 Jun; 16(2):177-82. PubMed ID: 9261744 [TBL] [Abstract][Full Text] [Related]
10. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. Lefebvre S; Antoine M; Uzan S; McMaster M; Dausset J; Carosella ED; Paul P J Pathol; 2002 Mar; 196(3):266-74. PubMed ID: 11857488 [TBL] [Abstract][Full Text] [Related]
11. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. Ottesen GL APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968 [TBL] [Abstract][Full Text] [Related]
12. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases. Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306 [TBL] [Abstract][Full Text] [Related]
13. HLA-G is a potential tumor marker in malignant ascites. Singer G; Rebmann V; Chen YC; Liu HT; Ali SZ; Reinsberg J; McMaster MT; Pfeiffer K; Chan DW; Wardelmann E; Grosse-Wilde H; Cheng CC; Kurman RJ; Shih IeM Clin Cancer Res; 2003 Oct; 9(12):4460-4. PubMed ID: 14555519 [TBL] [Abstract][Full Text] [Related]
14. High-resolution analysis of HLA class I alterations in colorectal cancer. Dierssen JW; de Miranda NF; Mulder A; van Puijenbroek M; Verduyn W; Claas FH; van de Velde CJ; Jan Fleuren G; Cornelisse CJ; Corver WE; Morreau H BMC Cancer; 2006 Oct; 6():233. PubMed ID: 17014712 [TBL] [Abstract][Full Text] [Related]
15. Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma. Weinman EC; Roche PC; Kasperbauer JL; Cha SS; Sargent DJ; Cheville J; Murphy LM; Chen L; Wettstein PJ; Gostout B; Ferrone S; Strome SE Cancer; 2003 May; 97(9):2203-11. PubMed ID: 12712472 [TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity at 6p21 underlying [corrected] HLA class I downregulation in Chinese primary esophageal squamous cell carcinomas. Yang Y; Zhang J; Miao F; Wei J; Shen C; Shen Y; Xie W Tissue Antigens; 2008 Aug; 72(2):105-14. PubMed ID: 18721270 [TBL] [Abstract][Full Text] [Related]
17. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Ogino T; Bandoh N; Hayashi T; Miyokawa N; Harabuchi Y; Ferrone S Clin Cancer Res; 2003 Sep; 9(11):4043-51. PubMed ID: 14519625 [TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity at 6p21.3 underlying HLA class I downregulation in gastric cancer. Wang XC; Zhang JQ; Shen YQ; Miao FQ; Xie W J Exp Clin Cancer Res; 2006 Mar; 25(1):115-9. PubMed ID: 16761627 [TBL] [Abstract][Full Text] [Related]
20. Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast. Geradts J; Ingram CD Mod Pathol; 2000 Sep; 13(9):945-53. PubMed ID: 11007034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]